Pharmacodynamic effect of N-acetylcysteine as adjunctive therapy in mild systemic lupus erythematosus patients

10Citations
Citations of this article
16Readers
Mendeley users who have this article in their library.

Abstract

Purpose: To evaluate the pharmacodynamic effect of N-acetylcysteine (NAC) in mild systemic lupus erythematosus (SLE) patients in order to implement NAC as adjunctive therapy in SLE population. Methods: Forty mild SLE patients were randomly allocated to receive 1800 mg of NAC with SLE standard therapy or receive standard therapy alone. Follow up was performed at 2 weeks, then every month up to 6 months. Glutathione GSH and malondialdehyde (MDA), a lipid peroxidation product in plasma, were measured at each visit; clinical symptoms were also evaluated. Results: Supplementation with 1800 mg of NAC did not significantly (p > 0.05) affect GSH level; however, MDA level was significantly (p < 0.05) decreased and the number of patients who could tapper prednisolone dosage was higher in the NAC group than in the control group. Conclusion: Administration of NAC may be beneficial in mild SLE patients in terms of decreasing lipid peroxidation. However, this conclusion does not apply to the effect of NAC at different dosages for moderate and severe SLE. Further studies are required in this regard © Pharmacotherapy Group, Faculty of Pharmacy, University of Benin, Benin City, 300001 Nigeria.

Cite

CITATION STYLE

APA

Tewthanom, K., Janwityanujit, S., Totemchockchyakarn, K., & Panomvana, D. (2011). Pharmacodynamic effect of N-acetylcysteine as adjunctive therapy in mild systemic lupus erythematosus patients. Tropical Journal of Pharmaceutical Research, 10(2), 141–146. https://doi.org/10.4314/tjpr.v10i2.66554

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free